Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 179 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

Multiple Sclerosis, Relapsing-Remitting Italy

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer Phase1 Israel

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Prostatic Neoplasms Phase3 United States

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

Ovarian Cancer, Lung Cancer Phase1 Israel

A Study of BION-1301 in Adults With IgA Nephropathy

IgA Nephropathy, Immunoglobulin A Nephropathy Phase3 Australia
United States
Argentina
Canada
Korea, Republic of
View All

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

IgA Nephropathy, Immunoglobulin A Nephropathy Phase2 Korea, Republic of
United States
Malaysia
Spain
Brazil
Australia
View All

A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)

Lupus Erythematosus, Systemic, Lupus Nephritis Phase2 United States
Singapore

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Sickle Cell Disease Phase1, Phase2 United States

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis Phase4 Germany
United Kingdom
United States

First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers

Healthy Volunteers Phase1 United Kingdom